SandboxAQ has announced that its AI-powered drug discovery models are now available through Anthropic’s Claude platform, allowing scientists and researchers to interact with advanced pharmaceutical simulation tools using natural language instead of requiring deep computational expertise. The move is designed to make complex drug development workflows more accessible to a broader range of researchers.
The integration allows users to access SandboxAQ’s Large Quantitative Models (LQMs) directly through Claude. Unlike traditional large language models that primarily generate text, LQMs are specialized AI systems trained to solve complex scientific and mathematical problems involving chemistry, biology, physics, and molecular simulation.
According to SandboxAQ CEO Jack Hidary, the partnership is intended to simplify advanced scientific computing workflows that previously required teams of highly specialized computational scientists. Researchers can now reportedly ask natural-language questions such as how a molecule might bind to a protein, what toxicity risks could emerge, or how certain compounds compare for drug development potential.
The system combines Claude’s conversational interface with SandboxAQ’s scientific reasoning models to create what the companies describe as a more intuitive AI-assisted research environment. Instead of manually running highly technical simulation pipelines, scientists can interact with the models conversationally while still receiving quantitative computational outputs and scientific analysis.
SandboxAQ has increasingly positioned itself at the intersection of AI, quantum-inspired computing, and scientific research. The company was spun out of Alphabet in 2022 and has attracted backing from major investors including Eric Schmidt, Breyer Capital, BNP Paribas, and Ray Dalio. Earlier this year, the company reportedly raised funding at a valuation exceeding $5 billion.
The company’s technology is already being used in partnerships with pharmaceutical and biotechnology companies focused on molecular modeling, biomarker discovery, materials science, and precision medicine. SandboxAQ argues that LQMs can significantly reduce the time and computational complexity involved in early-stage drug discovery and chemical analysis workflows.
The partnership also reflects a broader trend where AI companies are increasingly integrating specialized scientific models into conversational AI platforms. Rather than relying solely on general-purpose chatbots, enterprise AI providers are building domain-specific systems capable of handling complex workflows in healthcare, engineering, finance, and scientific research.
Industry analysts believe this convergence of conversational AI and scientific computation could significantly accelerate research productivity. By lowering technical barriers to advanced simulation and analysis tools, AI platforms may allow smaller research teams and non-specialist scientists to access capabilities that previously required dedicated computational infrastructure and highly trained modeling experts.
